drugset / Trial / NCT05813847

Herniorrhaphy for Postoperative Pain

NCT05813847

Phase 3 Completed 518 enrolled Cali Pharmaceuticals LLC
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Subjects receive either CPL-01, positive control, or negative control after herniorrhaphy and are then followed.

Timeline

Start
2023-04-18
Primary completion
2025-09-15
Completion
2025-10-06

Drugs

EvaluationDrugModalityDoseRoute
Subject CPL-01 Unknown Other
Comparator Ropivacaine Other / unclassified Other
Background Acetaminophen Small molecule Oral
Background Morphine Other / unclassified Intravenous
Background Oxycodone Other / unclassified Oral

Indications

No indication recorded.